The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | Access inequality to advanced myeloma therapies in low-to-middle-income countries
Vania Hungria, MD, PhD, Faculty of Medical Sciences of Santa Casa de São Paulo, Brazil, discusses the limited access to advanced myeloma therapies in low-to-middle-income countries. Although bispecific antibodies and cilta-cel are approved in Brazil, their availability in public institutions is restricted. A study revealed that patients treated in the public sector have inferior overall survival (OS) compared to those in the private sector, highlighting the urgent need to improve access to these treatments for all patients. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
